Response matters in light chain amyloidosis, whatever it takes

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Upfront daratumumab access for AL amyloidosis is increasing but not universal.
• Relapsed/refractory AL amyloidosis after initial bortezomib-based regimens presents a treatment challenge.
• The efficacy of second-line daratumumab-based therapy in this setting requires further investigation.

Purpose of the Study:

• To evaluate the response rates of second-line daratumumab, bortezomib, and dexamethasone (DVD) in patients with relapsed/refractory AL amyloidosis.
• To assess the effectiveness of DVD salvage therapy in patients who did not receive upfront daratumumab.

Main Methods:

• Retrospective analysis of patients with relapsed/refractory AL amyloidosis treated with second-line DVD.
• Evaluation of hematologic response rates and depth of response achieved with DVD therapy.
• Comparison of outcomes between patients who received upfront daratumumab and those who did not.

Main Results:

• Second-line DVD therapy demonstrated significant efficacy in relapsed/refractory AL amyloidosis.
• Patients not receiving upfront daratumumab could be effectively rescued with second-line DVD.
• Deep hematologic responses were achievable even with delayed daratumumab initiation.

Conclusions:

• Second-line daratumumab, bortezomib, and dexamethasone is an effective salvage strategy for relapsed/refractory AL amyloidosis.
• Deep hematologic response should be pursued tenaciously in AL amyloidosis, regardless of initial treatment.
• Daratumumab remains a valuable therapeutic option for AL amyloidosis patients who do not receive it upfront.